Postoperative change of anti-Thomsen-Friedenreich and Tn IgG level: The follow-up study of gastrointestinal cancer patients

Table 1 The effect of gastrectomy on the antibody level in patients with gastric cancer

Detection of antibodies	Mean ± SD	Increase	Median of difference1	Difference2		P (sign test)
				+	-
TF (n = 28)				20	8
Preoperative level	1.95 ± 1.86
Postoperative level	2.66 ± 2.61	36.4%	0.28			< 0.05
Tn (n = 29)				21	8
Preoperative level	2.64 ± 2.24
Postoperative level	3.36 ± 2.84	27.3%	0.38			< 0.05

¹Values of the postoperative (the first analysis after surgery) minus preoperative antibody level;

²The number of patients having the positive or negative difference.

Table 2 Postoperative changes of the level of antibodies in gastrointestinal tumor of different grades

Grade1	Detection of antibodies	Mean ± SD	Increase	Median of difference	Difference		P (sign test)
					+	-
G1 + G2 (n = 24)	TF, preoperative	2.03 ± 2.04
	postoperative	2.43 ± 2.86	19.7%	0.05	15	9
G3 (n = 27)	TF, preoperative	1.84 ± 1.71
	postoperative	3.03 ± 3.20	64.7%	0.29	22	5	< 0.01
G1 + G2 (n = 30)	Tn, preoperative	2.46 ± 1.80
	postoperative	2.99 ± 2.45	21.5%	0.12	18	12
G3 (n = 25)	Tn, preoperative	2.45 ± 2.18
	postoperative	3.15 ± 2.92	28.6%	0.42	19	6	< 0.05
G1 + G2 (n = 32)	αGal, preoperative	4.10 ± 2.55
	postoperative	4.62 ± 3.20	12.7%	0.17	20	12
G3 (n = 32)	αGal, preoperative	5.09 ± 3.34
	postoperative	6.61 ± 3.70	29.9%	1.20	24	8	< 0.01

¹G1+G2-well-and moderately-differentiated carcinomas.

Table 3 The percentage of patients with the mean level of anti-TF IgG above the cut-off value (1.53) by histological grading: The postoperative follow-up study

Cancer	G1 + G2		G3		χ2	P
	n	> cut-off	n	> cut-off
Gastric, all	22	9.1%	38	26.3%	2.58	0.108
Gastric, without metastases (N0)	16	6.2%	22	31.8%	3.64	0.056
Gastrointestinal, all	47	8.5%	47	23.4%	3.89	0.049
Gastrointestinal (N0)	35	5.7%	26	26.9%	5.34	0.021

Table 4 The percentage of patients with the mean level of anti-TF IgG above the cut-off value of 1.26 (responders) in relation to cancer progression: The postoperative follow-up study

Cancer	n	> cut-off	χ2	P
Gastric, N0	38	39.5%	2.92	0.088
Gastric, N1 + N2	22	18.9%
Gastric, stage I	24	41.7%	4.71	0.03
Gastric, stages III-IV	18	11.1%
Gastrointestinal, stage I	29	37.9%	4.11	0.043
Gastrointestinal, stages III-IV	28	14.3%